FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207040743> ?p ?o ?g. }

• W4207040743 abstract "Aim Oleocanthal and oleacein (OC/OL) have important in vitro and in vivo antitumor properties; however, there is no data about their anticancer activity in humans. The aim of this pilot study was to test if patients at early stage of chronic lymphocytic leukemia (CLL) could adhere to and tolerate an intervention with high OC/OL extra virgin olive oil (EVOO) and if this intervention could lead to any changes in markers related to the disease. Methods A pilot dietary intervention (DI) was made in patients with CLL in Rai stages 0–II who did not follow any treatment (NCT04215367). In the first intervention (DI1), 20 CLL patients were included in a blind randomized study and were separated into two groups. One group (A) of 10 patients consumed 40 ml/day of high OC/OL-EVOO (416 mg/Kg OC and 284 mg/kg OL) for 3 months. A second group (B) of 10 patients consumed 40 ml/day of low OC/OL (82 mg/kg OC and 33 mg/kg OL) for 3 months. After a washout period of 9–12 months, a second intervention (DI2) only with High OC/OL-EVOO for 6 months was performed with 22 randomly selected patients (16 from the DI1 (8 from each group) and 6 new). Hematological, biochemical, and apoptotic markers were analyzed in the serum of the patients. In addition, cellular proliferation and apoptosis markers were studied in isolated proteins from peripheral blood mononuclear cells. Results The results of the DI1 showed beneficial effects on hematological and apoptotic markers only with High OC/OL-EVOO. During the DI2, a decrease in the white blood cell and lymphocyte count was observed (p ≤0.05), comparing 3 months before the intervention and 6 months after it. After 3 and 6 months of DI2, an increase (p ≤0.05) was observed in the apoptotic markers ccK18 and Apo1-Fas, and also in the cell cycle negative regulator p21, and also a decrease in the antiapoptotic protein Survivin, and in the cellular proliferation marker Cyclin D. Conclusions This is the first clinical trial with High OC/OL-EVOO that indicates that it could be a promising dietary feature for the improvement of CLL inducing the apoptosis of their cancer cells and improving the metabolism of the patients. Clinical Trial Registration https://clinicaltrials.gov/ct2/show/NCT04215367 , identifier: NCT04215367." @default.
• W4207040743 created "2022-01-26" @default.
• W4207040743 creator A5009368931 @default.
• W4207040743 creator A5010482917 @default.
• W4207040743 creator A5021038189 @default.
• W4207040743 creator A5022662912 @default.
• W4207040743 creator A5040839300 @default.
• W4207040743 creator A5059685093 @default.
• W4207040743 creator A5061287410 @default.
• W4207040743 creator A5067388327 @default.
• W4207040743 creator A5071264424 @default.
• W4207040743 date "2022-01-21" @default.
• W4207040743 modified "2023-10-17" @default.
• W4207040743 title "The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomized Trial" @default.
• W4207040743 cites W154103547 @default.
• W4207040743 cites W1565211228 @default.
• W4207040743 cites W1574333999 @default.
• W4207040743 cites W1853943513 @default.
• W4207040743 cites W1965851569 @default.
• W4207040743 cites W1970368646 @default.
• W4207040743 cites W1971873029 @default.
• W4207040743 cites W1978710215 @default.
• W4207040743 cites W2011980743 @default.
• W4207040743 cites W2022736043 @default.
• W4207040743 cites W2032435072 @default.
• W4207040743 cites W2037049243 @default.
• W4207040743 cites W2042152044 @default.
• W4207040743 cites W2055309496 @default.
• W4207040743 cites W2095319004 @default.
• W4207040743 cites W2097259163 @default.
• W4207040743 cites W2133717355 @default.
• W4207040743 cites W2140336909 @default.
• W4207040743 cites W2141386379 @default.
• W4207040743 cites W2145185496 @default.
• W4207040743 cites W2150838826 @default.
• W4207040743 cites W2155215362 @default.
• W4207040743 cites W2191746047 @default.
• W4207040743 cites W2430283214 @default.
• W4207040743 cites W2462486041 @default.
• W4207040743 cites W2465355086 @default.
• W4207040743 cites W2727166420 @default.
• W4207040743 cites W2758902329 @default.
• W4207040743 cites W2801835795 @default.
• W4207040743 cites W2892430625 @default.
• W4207040743 cites W2894238189 @default.
• W4207040743 cites W2944281631 @default.
• W4207040743 cites W2958425042 @default.
• W4207040743 cites W2967579196 @default.
• W4207040743 cites W2968487504 @default.
• W4207040743 cites W2996586177 @default.
• W4207040743 cites W3089292234 @default.
• W4207040743 cites W3092447331 @default.
• W4207040743 cites W3109168993 @default.
• W4207040743 cites W3118556989 @default.
• W4207040743 cites W3125563011 @default.
• W4207040743 cites W3157092249 @default.
• W4207040743 cites W966445620 @default.
• W4207040743 doi "https://doi.org/10.3389/fonc.2021.810249" @default.
• W4207040743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35127522" @default.
• W4207040743 hasPublicationYear "2022" @default.
• W4207040743 type Work @default.
• W4207040743 citedByCount "11" @default.
• W4207040743 countsByYear W42070407432022 @default.
• W4207040743 countsByYear W42070407432023 @default.
• W4207040743 crossrefType "journal-article" @default.
• W4207040743 hasAuthorship W4207040743A5009368931 @default.
• W4207040743 hasAuthorship W4207040743A5010482917 @default.
• W4207040743 hasAuthorship W4207040743A5021038189 @default.
• W4207040743 hasAuthorship W4207040743A5022662912 @default.
• W4207040743 hasAuthorship W4207040743A5040839300 @default.
• W4207040743 hasAuthorship W4207040743A5059685093 @default.
• W4207040743 hasAuthorship W4207040743A5061287410 @default.
• W4207040743 hasAuthorship W4207040743A5067388327 @default.
• W4207040743 hasAuthorship W4207040743A5071264424 @default.
• W4207040743 hasBestOaLocation W42070407431 @default.
• W4207040743 hasConcept C126322002 @default.
• W4207040743 hasConcept C137061746 @default.
• W4207040743 hasConcept C146357865 @default.
• W4207040743 hasConcept C151730666 @default.
• W4207040743 hasConcept C168563851 @default.
• W4207040743 hasConcept C190283241 @default.
• W4207040743 hasConcept C202751555 @default.
• W4207040743 hasConcept C2777938653 @default.
• W4207040743 hasConcept C2778461978 @default.
• W4207040743 hasConcept C2988377048 @default.
• W4207040743 hasConcept C31903555 @default.
• W4207040743 hasConcept C55493867 @default.
• W4207040743 hasConcept C71924100 @default.
• W4207040743 hasConcept C86803240 @default.
• W4207040743 hasConcept C90924648 @default.
• W4207040743 hasConcept C98274493 @default.
• W4207040743 hasConceptScore W4207040743C126322002 @default.
• W4207040743 hasConceptScore W4207040743C137061746 @default.
• W4207040743 hasConceptScore W4207040743C146357865 @default.
• W4207040743 hasConceptScore W4207040743C151730666 @default.
• W4207040743 hasConceptScore W4207040743C168563851 @default.
• W4207040743 hasConceptScore W4207040743C190283241 @default.
• W4207040743 hasConceptScore W4207040743C202751555 @default.
• W4207040743 hasConceptScore W4207040743C2777938653 @default.
• W4207040743 hasConceptScore W4207040743C2778461978 @default.

• next